NVO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk's Wegovy wins UK approval, targeting MASH liver disease
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk's Wegovy (semaglutide injection) for metabolic-associated...
🟢 NVO is trading 3.1% up today after Medicare launches GLP-1 Bridge program for Wegovy
NVO is trading 3.1% up now at $50.30 after Medicare officially launched its GLP-1 Bridge program for obesity drug Wegovy, expanding coverage with a $50 monthly...
🟢 NVO is trading 3.2% up today as Medicare launches GLP-1 Bridge program for Wegovy
NVO is trading 3.2% up at $49.48 as Medicare’s GLP-1 Bridge program officially launches, significantly expanding insurance coverage for Novo Nordisk’s obesity...
Medicare Opens Its Wallet for Wegovy Tomorrow — Can Volume Overcome Novo Nordisk's Pricing Squeeze?
Shares edged higher as Novo Nordisk prepares for what may be the most consequential shift in its U.S. commercial landscape in years: millions of Medicare...
Novo Nordisk gains as Medicare covers Wegovy, launching $50 co-pay pilot
The U.S. Centers for Medicare & Medicaid Services (CMS) will launch the Medicare GLP-1 Bridge pilot program on July 1, 2026. This initiative marks the first...
Novo Nordisk's U.S. Chief Aims for More Insurance Coverage for Wegovy
Novo Nordisk's top U.S. executive, Jamey Millar, aims to increase the portion of Wegovy sales covered by health insurance. Out-of-pocket purchases currently...
Novo Nordisk Wins a Court Battle Over Copycat Drugs in South Africa — But Can Legal Victories Alone Reverse a Stock in Freefall?
Shares surged as Novo Nordisk scored a rare win in its fight to protect its weight-loss empire. South Africa's High Court granted an interim order blocking...
🟢 NVO is trading 4.7% up today after legal win against unapproved Ozempic copies
NVO is trading 4.7% up at $49.65 in after-hours trading after Novo Nordisk secured a South African High Court order halting sales of unapproved Ozempic and...
Novo Nordisk halts South African sales of unapproved Ozempic, Wegovy copies
Novo Nordisk secured a High Court interim order in South Africa to halt the sale of unapproved weight-loss drugs. The ruling prevents local pharmacy group...
🟢 Novo Nordisk A/S extends move to 5.1% up
NVO is trading at $45.40, up 5.1% versus the comparison close of $43.19 during regular trading. This is a price-movement alert; no separate company-specific...
Novo Nordisk expects generic semaglutide in China by 2027, as protections end
Novo Nordisk expects generic versions of semaglutide to enter the Chinese market in the second quarter of 2027. CEO Mike Doustdar announced the timeline during...
Novo Nordisk Foundation launches $69M hub, accelerating European obesity drug discovery
The Novo Nordisk Foundation is launching CardioMetabolic Bridge, a pan-European initiative to accelerate drug discovery for obesity and type 2 diabetes. The...
🟢 Novo Nordisk A/S is trading 4.3% up today on plans to seek Chinese approval for oral Wegovy
Novo Nordisk A/S is trading 4.3% up at $45.41 following reports that the company plans to seek Chinese regulatory approval for an oral version of its...
Novo Nordisk seeks China approval for oral Wegovy, challenging Eli Lilly
Novo Nordisk plans to submit its oral version of the weight-loss drug Wegovy for regulatory approval in China. CEO Mike Doustdar announced on June 16 that the...
Novo Nordisk Wins UK Approval for Oral Wegovy, First in Europe
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk’s daily oral version of its weight-loss drug, Wegovy. This...
Novo Nordisk draws 10,000 UK sign-ups for oral Wegovy, expanding the market
Novo Nordisk’s oral version of Wegovy attracted over 10,000 people to a waiting list at UK pharmacy Chemist4U. This high interest signals strong demand for a...
🟢 Novo Nordisk A/S is trading 4.3% up today as investors reassess obesity drug trial data
Novo Nordisk A/S is trading 4.3% up today at $43.99 as investors provide a more constructive reassessment of recent obesity drug trial data. • The stock is...
Novo Nordisk Shares Slide, Despite Amycretin Delivering 14.6% Weight Loss
Novo Nordisk presented Phase 2 trial data for its investigational drug amycretin at the American Diabetes Association's 2026 Scientific Sessions. The...
🔴 Novo Nordisk A/S is trading 4% down today as market re-evaluates Ozempic vs. Mounjaro competition
Novo Nordisk A/S is trading 4% down at $41.24 as investors react to fresh data comparing Ozempic and Eli Lilly’s Mounjaro in type 2 diabetes. • Real-world...
Novo Nordisk says Ozempic matches Mounjaro, citing superior weight loss data
Novo Nordisk released real-world data comparing Ozempic to Eli Lilly’s Mounjaro for type 2 diabetes. The study analyzed patients already taking a 1 mg dose of...